Financial Data and Key Metrics Changes - Fiscal 2025 Adjusted EBITDA reached $352 million, an increase of $28 million or 8% compared to fiscal 2024, with a margin of 13.2%, representing a 260 basis point improvement from fiscal 2023 [14][15] - Adjusted EBITDA margin expanded by 150 basis points year-over-year, marking consecutive years of margin expansion [15][20] - SG&A expense as a percentage of revenue improved by 180 basis points since 2023, reflecting operational efficiencies [12][16] Business Line Data and Key Metrics Changes - Customer retention improved to approximately 83%, a 400 basis point increase since the start of the transformation two years ago [8][4] - The company added about 100 new sellers in fiscal 2025, with plans to continue expanding the sales force by approximately 500 net new hires through 2030 [9][10] - The land maintenance revenue is expected to grow by 1%-2% in fiscal 2026, driven by the growing sales force and improved customer retention [21] Market Data and Key Metrics Changes - The development segment is expected to see revenue growth in the range of flat to +2%, supported by a healthy backlog and benefits from cold starts [22] - Snow revenue is anticipated to be between $190 million and $220 million, reflecting a shift to more fixed fee contracts [22] Company Strategy and Development Direction - The company is focused on delivering sustainable and profitable top-line growth by investing in frontline employees and expanding the sales force [6][11] - A disciplined approach to capital allocation is emphasized, with an increased share repurchase authorization from $100 million to $150 million [4][19] - The fleet management strategy has been a key focus, with over $300 million invested to refresh aging equipment, leading to improved operational efficiency and employee morale [18][19] Management's Comments on Operating Environment and Future Outlook - Management expressed optimism about the return of discretionary spending in ancillary services and the overall growth potential for the business in 2026 [28][29] - The company is confident in its ability to grow, citing improvements in employee and customer retention as critical factors [84][85] - Management acknowledged potential challenges from seasonal fluctuations but remains focused on leveraging improvements in service delivery and operational efficiencies [28][29] Other Important Information - The company has a strong balance sheet with net leverage remaining at 2.3x and no long-term maturities until 2029, providing ample liquidity for investments [19][20] - The midpoint of the margin guidance implies a 310 basis point improvement over the last three years, reinforcing the commitment to expanding margins [23] Q&A Session Summary Question: How did performance in discretionary areas of land maintenance trend in Q4? - Management noted optimism in discretionary spending returning, with positive feedback from frontline workers and customers regarding new fleet investments [27][28] Question: What is the expected productivity ramp for new sales hires? - New sellers typically see limited productivity in the first six months, with improved performance expected after a year, targeting $1.5 million in annual sales for seasoned sellers [30][31] Question: How far along is the company in improving employee retention? - Employee retention has improved significantly, with further potential for enhancement, aiming for a more normalized level for the high-turn workforce [41][43] Question: What impact has the new tax bill had on capital investment? - The company benefited from tax savings to accelerate fleet refresh investments, with expectations to normalize capital expenditures in the coming years [45][46] Question: What is the timeline for the rollout of the field service management system? - The rollout is expected to be completed in the first quarter of the new year, aimed at increasing efficiency and capacity rather than cost savings [68][69] Question: How are project delays in the development business being managed? - Management indicated that while there have been delays, they expect to see growth in the development business as new branches open and backlogs are addressed [71][72]

Financial Data and Key Metrics Changes - Neurocrine Biosciences reported $790 million in net product sales for Q3 2025, reflecting a 28% year-over-year growth driven by INGREZZA and CRENESSITY [6][10] - CRENESSITY's sales grew from $53 million in Q2 to $98 million in Q3, indicating strong early adoption and persistency rates [6][7] - INGREZZA achieved net sales of $687 million in Q3, marking the third consecutive quarter of record new patient additions [7][10] Business Line Data and Key Metrics Changes - INGREZZA's performance has been exceptional, with a prescriber base that has expanded by 30% over the past two years, reflecting the strong clinical profile and unmet need for tardive dyskinesia treatment [10][11] - CRENESSITY has seen 540 new patients initiate therapy in Q3, bringing the total to over 1,600 since its launch [13][15] - The company anticipates continued growth for both products, with plans for further sales force expansion to maximize patient share [8][16] Market Data and Key Metrics Changes - The tardive dyskinesia market is expected to grow significantly, with only about 10% of diagnosed patients currently treated with a VMAT2 inhibitor, indicating substantial growth potential for INGREZZA [10][11] - The congenital adrenal hyperplasia (CAH) community has shown favorable feedback towards CRENESSITY, with 80% of dispensed prescriptions now being reimbursed [6][15] Company Strategy and Development Direction - Neurocrine Biosciences is focused on expanding its sales force for both INGREZZA and CRENESSITY to accelerate growth into 2026 and beyond [4][8] - The company aims to drive revenue growth, advance R&D programs, enable business development, and return capital to shareholders, with a strong financial profile of over $2.1 billion in cash [9][80] - The strategic expansion of the sales force is intended to maximize patient share and prepare for anticipated launches of investigational psychiatric medicines [8][12] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the ongoing momentum for both products and the potential for sustained long-term growth driven by their science and commitment to patients [5][9] - The company remains on track for its clinical programs, with anticipated top-line results for key studies in the near future [18][19] - Management acknowledged the potential impacts of the Inflation Reduction Act (IRA) on the market and emphasized the importance of maximizing patient share before 2027 [8][30] Other Important Information - The company is fully cooperating with a Department of Justice investigation related to the sales and marketing of INGREZZA, maintaining a robust compliance program [40][41] - The sales force expansion is expected to result in an increase in SG&A expenses of around $150 million in 2026 [9][79] Q&A Session Summary Question: Insights on patient dynamics and starts for CRENESSITY - Management noted that the adoption of CRENESSITY has been strong, with 540 new treatment forms in Q3, and they do not believe there are significant seasonal dynamics affecting enrollment [22][23] Question: Implications of the IRA on pricing and reimbursement - Management is monitoring the upcoming Oscado pricing and its potential effects on INGREZZA, emphasizing the importance of maximizing patient numbers before the IRA impacts [28][30] Question: Status of reimbursement requirements for CRENESSITY - Management indicated that reimbursement has been smooth, with no specific requirements for steroid tapering to continue coverage [34] Question: Sales force expansion details - The expansion is characterized as a 30% increase in overall sales footprint, primarily targeting psychiatry and neurology for INGREZZA, while also expanding the team for CRENESSITY [46][48] Question: Update on the Department of Justice investigation - Management confirmed they are cooperating with the DOJ regarding a civil investigative demand related to INGREZZA's sales and marketing practices [40][41] Question: Progress with CRENESSITY at centers of excellence - All centers of excellence have started adopting CRENESSITY, with varying rates of adoption, and there is optimism about community endocrinologists' engagement [43][44]